

Literatura ACTA MEDICINAE 14/2024 Vnitřní lékařství

- 3 **Výběr nevhodnějšího antikoagulantů v různých indikacích pro specifické nemocné**
prof. MUDr. Jan Bultas, CSc. Ústav farmakologie 3. LF UK, Praha
- 3 **Současné možnosti léčby hluboké žilní trombózy**
MUDr. Zdislava Štulcová III. interní klinika, 1. LF UK a VFN v Praze
- 3 **Arteriální hypertenze u mladých dospělých**
prof. MUDr. Jitka Mlíková Seidlerová, Ph.D. II. interní klinika, LF UK a FN v Plzni
- 3 **Deprese a kardiovaskulární poruchy: mají něco společného?**
doc. MUDr. Dana Končelíková Kamarádová, Ph.D. Klinika psychiatrie, FN Olomouc
- 4 **Sertralinem vedená léčba deprese u osob po infarktu myokardu či s nestabilní anginou pectoris**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Nebivolol v léčbě arteriální hypertenze a srdečního selhání**
doc. MUDr. Ondřej Petrák, Ph.D. Centrum pro výzkum, diagnostiku a léčbu arteriální hypertenze, III. interní klinika – klinika endokrinologie a metabolismu, VFN a 1. LF UK, Praha
- 4 **Použití landiololu u pacientky se srdečním selháním a supraventrikulární tachykardií – kazuistika**
MUDr. Aneta Dvořáková Kardiologické oddělení, Nemocnice Na Homolce, Praha M
MUDr. Andreas Krüger, Ph.D. Kardiologické oddělení, vedoucí lékař, Nemocnice Na Homolce, Praha
- 5 **Arytmie v praxi – kazuistiky**
MUDr. Marek Šramko, Ph.D., FESC IKEM, Praha
- 5 **Role kardio-reno-metabolického syndromu v prevenci častých chronických onemocnění**
prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, II. interní klinika LF UK a Fakultní nemocnice Plzeň
- 5 **Postavení rivaroxabanu v dávce 2,5 mg v současné medicíně**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 5 **Zkušenosti s canagliflozinem v běžné klinické praxi**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 5 **Optimalizace hemoglobinu v předoperační přípravě pacientů podstupujících implantaci totálních náhrad kyčelního a kolenního kloubu**
MUDr. Vít Lorenc, MBA Anesteziologicko-resuscitační oddělení, Nemocnice Jindřichův Hradec, a. s.
- 6 **NAFLD – MAFLD – MASLD. Jak se vyznat ve zkratkách těchto onemocnění?**
doc. MUDr. Lukáš Zlatohlávek, Ph.D. | MUDr. Jana Beňová Becherová
III. interní klinika – klinika endokrinologie a metabolismu, 1. LF UK a VFN, Praha
- 6 **Terapie průjmů neinfekčního původu**
PharmDr. MVDr. Vilma Vranová, Ph.D. Ústav aplikované farmacie, Farmaceutická fakulta MUNI, Brno
- 6 **Biologická a cílená léčba u idiopatických střevních zánětů**
prof. MUDr. Milan Lukáš, CSc., AGAF Klinické a výzkumné centrum pro idiopatické střevní záněty; Klinické centrum ISCARE, a. s., a 1. LF UK, Praha
- 6 **Diferenciální diagnostika intersticiálních plicních procesů pro praxi**
doc. MUDr. Martina Štercllová, Ph.D. Pneumologická klinika, 2. LF UK a FN v Motole; Pneumologická klinika, 1. LF UK a FTN, Praha
- 7 **Co nového v pneumologii**
doc. MUDr. Kristián Brat, Ph.D. Klinika nemocí plicních a tuberkulózy, LF MU a FN Brno
MUDr. Monika Bratová, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno; LF MU, Brno
- 7 **Nová antiobezitika**
prof. MUDr. Štěpán Svačina, DrSc., MBA III. interní klinika, 1. LF UK a VFN, Praha
- 7 **Antidiabetika v ordinaci internisty**
prof. MUDr. Milan Kvapil, CSc., MBA | MUDr. Martina Nováková Geriatrická interní klinika, 2. LF UK a FN v Motole, Praha

- 7 **Klinické projevy chronické hypotyreózy**
MUDr. Karolína Drbalová | MUDr. Mikuláš Kosák, Ph.D. | MUDr. Monika Nývltová
Interní klinika 1. LF UK a Ústřední vojenské nemocnice – Vojenské fakultní nemocnice, Praha
- 8 **Stabilizace hladiny TSH u pacientky s autoimunitní tyreoiditidou – kazuistika**
MUDr. Tereza Grimmichová Endokrinologický ústav, Praha, Interní klinika, FN Královské Vinohrady a 3. LF UK, Praha
- 8 **Hořčík a stres – circulus vitiosus...**
MUDr. Jarmila Křížová, Ph.D. III. interní klinika, 1. LF UK a VFN, Praha
- 8 **Klinická doporučení v prevenci a léčbě dekubitů – v kontextu základních ošetrovatelských intervencí**
prof. PhDr. Andrea Pokorná, Ph.D. Ústav zdravotnických věd, Lékařská fakulta, Masarykova univerzita, Brno
- 8 **Novinky v léčbě HIV a pozitivní dopad na prognózu pacientů**
doc. MUDr. Svatava Snopková, Ph.D. | prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob, LF MU a FN Brno-Bohunice
- 9 **Farmakoterapie v těhotenství**
doc. MUDr. Michal Koucký, Ph.D. Klinika gynekologie, porodnictví a neonatologie, 1. LF UK a VFN, Praha
- 9 **Sarkopenie a sarkopenická obezita u seniorů**
MUDr. Darina Matvejeva Geriatrická interní klinika, 2. LF UK a FN v Motole, Praha

Výběr nejvhodnějšího antikoagulantia v různých indikacích pro specifické nemocné

prof. MUDr. Jan Bultas, CSc. Ústav farmakologie 3. LF UK, Praha

- 1 Bolek, T. – Samoř, M. – Stančíková, L., et al.: The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. *Am J Ther*, 2019, 26, s. e308.
- 2 Bracey, A. – Shatila, W. – Wilson, J.: Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. *Ther Adv Cardiovasc Dis*, 2018, 12, s. 361–380.
- 3 Steffel, J. – Verhamme, P. – Potpara, T. S., et al.: The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J*, 2018, 39, s. 1330–1393.
- 4 Joosten, L. P. T. – van Doorn, S. – van de Ven, P. M., et al.: Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. *Circulation*, 2024, 149, s. 279–289.

Současné možnosti léčby hluboké žilní trombózy

MUDr. Zdislava Štulcová III. interní klinika, 1. LF UK a VFN v Praze

- 1 Hirmerová, J. – Karetová, D. – Malý, R., et al.: Akutní žilní trombóza: Současný stav prevence, diagnostiky a léčby: Aktualizace 2020. Doporučený postup České angiologické společnosti ČLS JEP. Dostupné z: https://www.angiology.cz/Angiology/media/system/guidelines/DP_CAS_akutni_zilni_tromboza_2020.pdf, vyhledáno 7. 10. 2024.
- 2 Ortel, T. – Neumann, I. – Ageno, W., et al.: American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism. *Blood Adv*, 2020, 4, s. 4693–4738.
- 3 Kakkos, S. K. – Gohel, M. – Baekgaard, N., et al.: European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis 5. *Eur J Vasc Endovasc Surg*, 2021, 61, 9e82.
- 4 Čížek, V., et al.: Kavální filtry u pacientů s žilní trombózou. *Interní Med*, 2015, 17, s. 114–116.

Arteriální hypertenze u mladých dospělých

prof. MUDr. Jitka Mlíková Seidlerová, Ph.D. II. interní klinika, LF UK a FN v Plzni

- 1 Cifková, R. – Bruthans, J. – Wohlfahrt, P., et al.: 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985–2016/17. *PLoS One*, 2020, 15, e0232845.
- 2 Kearney, P. M. – Whelton, M. – Reynolds, K., et al.: Global burden of hypertension: analysis of worldwide data. *Lancet*, 2005, 365, s. 217–223.
- 3 Song, P. – Zhang, Y. – Yu, J., et al.: Global prevalence of hypertension in children: a systematic review and meta-analysis. *JAMA pediatrics*, 2019, 173, s. 1154–1163.
- 4 Garrison, R. J. – Kannel, W. B. – Stokes, J., et al.: Incidence and precursors of hypertension in young adults: The Framingham offspring study. *Prev Med*, 1987, 16, s. 235–251.
- 5 Bruno, R. M. – Pucci, G. – Rosticci, M., et al.: Association between life-style and systemic arterial hypertension in young adults: a national, survey-based, cross-sectional study. *High Blood Press Cardiovasc Prev*, 2016, 23, s. 31–40.
- 6 Scherrer, U. – Rexhaj, E. – Allemann, Y., et al.: Cardiovascular dysfunction in children conceived by assisted reproductive technologies. *Eur Heart J*, 2015, 36, s. 1583–1589.
- 7 Zhang, Y. – Moran, A. E.: Trends in the prevalence, awareness, treatment, and control of hypertension among young adults in the United States, 1999 to 2014. *Hypertens*, 2017, 70, s. 736–742.
- 8 Widimský, J. – Filipovský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2022. Doporučení České společnosti pro hypertenzi. *Hypertenze Kardiovaskulární Prevence*, 2022, suppl. 25. Dostupné z: https://www.hypertension.cz/wp-content/uploads/2023/01/Widimsky_guidelines-CSH-2022.pdf, vyhledáno 23. 7. 2024.
- 9 Visseren, F. L. J. – Mach, F. – Smulders, Y. M., et al.: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). *Eur Heart J*, 2021, 42, s. 3227–3337.
- 10 Xiong, Z. – Li, J. – Lin, Y., et al.: Intensity of hypertensive exposure in young adulthood and subclinical atherosclerosis in middle age: Evidence from the CARDIA study. *Front Cardiovasc Med*, 2022, 9, 959146.
- 11 Haight, T. – Nick Bryan, R. – Erus, G., et al.: White matter microstructure, white matter lesions, and hypertension: An examination of early surrogate markers of vascular-related brain change in midlife. *NeuroImage Clin*, 2018, 18, s. 753–761.
- 12 Bae, E. H. – Lim, S. Y. – Jung, J. H., et al.: Chronic kidney disease risk of isolated systolic or diastolic hypertension in young adults: a nationwide sample based-cohort study. *J Am Heart Association*, 2021, 10, e019764.
- 13 Lee, S. R. – Han, K. D. – Choi, E. K., et al.: Risk of atrial fibrillation in young adults with isolated diastolic, isolated systolic, and systolic-diastolic hypertension. *Hypertens*, 2021, 78, s. 1248–1258.
- 14 Broderick, M. – Rosignoli, L. – Lunagariya, A., et al.: Hypertension is a leading cause of nontraumatic intracerebral hemorrhage in young adults. *J Stroke Dis*, 2020, 29, 104719.
- 15 Palatini, P. – Rosè, E. A. – Avolio, A., et al.: Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension. *J Hypertens*, 2018, 36, s. 1222–1236.
- 16 Kanegae, H. – Oikawa, T. – Okawara, Y., et al.: Which blood pressure measurement, systolic or diastolic, better predicts future hypertension in normotensive young adults? *J Clin Hypertens*, 2017, 19, s. 603–610.
- 17 Stergiou, G. S. – Palatini, P. – Parati, G., et al.: 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. *J Hypertens*, 2021, 39, s. 1293–1302.
- 18 Stergiou, G. S. – Mukkamala, R. – Avolio, A., et al.: Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. *J Hypertens*, 2022, 40, s. 1449–1460.
- 19 Cifková, R.: Hypertension in pregnancy: a diagnostic and therapeutic overview. *High Blood Press Cardiovasc Prev*, 2023, 30, s. 289–303.

Deprese a kardiovaskulární poruchy: mají něco společného?

doc. MUDr. Dana Končelíková Kamarádová, Ph.D. Klinika psychiatrie, FN Olomouc

- 1 Alonso, J. – Angermeyer, M. C. – Bernert, S., et al.: ESEMED/MHEDEA 2000 Investigators: Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMED) project. *Acta Psychiatrica Scandinavica*, 2004, 109, s. 21–27.
- 2 Winkler, P. – Mohrova, Z. – Mlada, K., et al.: Prevalence of current mental disorders before and during the second wave of COVID-19 pandemic: An analysis of repeated nationwide cross-sectional surveys. *J Psychiatr Res*, 2021, 139, s. 167–171.
- 3 Hinton, W. – McGovern, A. – Coyle, R., et al.: Incidence and prevalence of cardiovascular disease in English primary care: a cross-sectional and follow-up study of the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC). *BMJ open*, 2012, 8, e020282.
- 4 Arnold, N. – Lechner, K. – Waldeyer, C.: Inflammation and cardiovascular disease: the future. *Eur Cardiol*, 2021, 16, s. e20.
- 5 Beurel, E. – Toups, M. – Nemeroff, C. B.: The bidirectional relationship of depression and inflammation: double trouble. *Neuron*, 2020, 107, s. 234–256.
- 6 Salas-Venegas, V. – Flores-Torres, R. P. – Rodríguez-Cortés, Y. M., et al.: The obese brain: mechanisms of systemic and local inflammation, and interventions to reverse the cognitive deficit. *Front Integr Neurosci*, 2022, 16, 798995.
- 7 Arnold, N. – Lechner, K. – Waldeyer, C.: Inflammation and cardiovascular disease: the future. *Eur Cardiol*, 2021, 16, s. e20.
- 8 Dubois-Deruy, E. – Peugnet, V. – Turkieh, A., et al.: Oxidative stress in cardiovascular diseases. *Antioxidants*, 2020, 9, s. 864.
- 9 Xu, J. – Mo, L. – Wu, Z.: A cross-sectional study on risk factors of depression severity among survivors of the 2008 Sichuan earthquake. *Community Ment Health J*, 2013, 49, s. 847–856.
- 10 Leor, J. – Poole, W. K. – Kloner, R. A.: Sudden cardiac death triggered by an earthquake. *N Engl J Med*, 1996, 334, s. 413–419.
- 11 Dierker, L. C. – Avenevoli, S. – Stolar, M., et al.: Smoking and depression: an examination of mechanisms of comorbidity. *Am J Psychiatry*, 2002, 159, s. 947–953.
- 12 Grant, B. F.: Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. *J Subst Abuse*, 1995, 7, s. 481–497.
- 13 Stunkard, A. J. – Faith, M. S. – Allison, K. C.: Depression and obesity. *Biol Psychiatry*, 2003, 54, s. 330–337.
- 14 Ukončené případy pracovní neschopnosti i pro nemoc a úraz 2021. Ústav zdravotnických informací a statistiky ČR. Praha 2022, s. 1–94. Dostupné z: <https://www.uzis.cz/index.php?pg=record&id=8412>, vyhledáno 9. 8. 2024.
- 15 Niles, A. N. – O'Donovan, A.: Comparing anxiety and depression to obesity and smoking as predictors of major medical illnesses and somatic symptoms. *Health Psychol*, 2019, 38, s. 172.
- 16 Dierker, L. C. – Avenevoli, S. – Stolar, M., et al.: Smoking and depression: an examination of mechanisms of comorbidity. *Am J Psychiatry*, 2002, 159, s. 947–953.
- 17 Ziegelstein, R. C. – Fauerbach, J. A. – Stevens, S. S., et al.: Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. *Arch Intern Med*, 2000, 160, s. 1818–1823.

Sertralinem vedená léčba deprese u osob po infarktu myokardu či s nestabilní anginou pectoris

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Krittanawong, C. – Maitra, N. S. – Qadeer, Y. K., et al.:** Association of depression and cardiovascular disease. *Am J Med*, 2023, 136, s. 881–895.
- 2 **Shapiro, P. A. – Lespérance, F. – Frasure-Smith, N., et al.:** An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial).
- 3 **Glassman, A. H. – O'Connor, C. M. – Califf, R. M., et al.:** Sertraline treatment of major depression in patients with acute MI or unstable angina. *JAMA*, 2002, 288, s. 701–709.
- 4 **Maslej, M. M. – Bolker, B. M. – Russell, M. J., et al.:** The mortality and myocardial effects of antidepressants are moderated by preexisting cardiovascular disease: a meta-analysis. *Psychother Psychosom*, 2017, 86, s. 268–282.
- 5 **Prasitlumkum, N. – Cheungpasitporn, W. – Tokavanich, N., et al.:** Antidepressants and risk of sudden cardiac death: a network meta-analysis and systematic review. *Med Sci*, 2021, 9, s. 26.

Nebivolol v léčbě arteriální hypertenze a srdečního selhání

doc. MUDr. Ondřej Petrák, Ph.D. Centrum pro výzkum, diagnostiku a léčbu arteriální hypertenze, III. interní klinika – klinika endokrinologie a metabolismu, VFN a 1. LF UK, Praha

- 1 **Marketou, M., et al.:** Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol. *Curr Hypertens Rep*, 2017, 19, s. 22.
- 2 **Mancia, G. – Kreutz, R. – Brunström, M., et al.:** 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens*, 2023, 41, s. 1874–2071.
- 3 **Widimský, J., et al.:** Diagnostické a léčebné postupy u arteriální hypertenze. Doporučení České společnosti pro hypertenzi. *Hypertenze & kardiovaskulární prevence*, 2022, 12, s. 1–27.
- 4 **Van de Water, A., et al.:** Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. *J Cardiovasc Pharmacol*, 1988, 11, s. 552–563.
- 5 **Gupta, S. – Wright, H. M.:** Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. *Cardiovasc Ther*, 2008, 26, s. 189–202.
- 6 **Toblli, J. E., et al.:** Nebivolol: impact on cardiac and endothelial function and clinical utility. *Vasc Health Risk Manag*, 2012, 8, s. 151–160.
- 7 **Maffei, A., et al.:** Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. *Hypertension*, 2007, 50, s. 652–656.
- 8 **Forstermann, U. – Munzel, T.:** Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Circulation*, 2006, 113, s. 1708–1714.
- 9 **Ignarro, L. J.:** Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol. *Cardiovasc Ther*, 2008, 26, s. 115–134.
- 10 **Mason, R. P., et al.:** Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity. *J Cardiovasc Pharmacol*, 2006, 48, s. 862–869.
- 11 **Bordicchia, M., et al.:** Nebivolol induces, via beta3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes. *J Hypertens*, 2014, 32, s. 389–396.
- 12 **Punzi, H., et al.:** Efficacy and safety of nebivolol in Hispanics with stage I–II hypertension: a randomized placebo-controlled trial. *Ther Adv Cardiovasc Dis*, 2010, 4, s. 349–357.
- 13 **Van Bortel, L. M. – Fici, F. – Mascagni, F.:** Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs*, 2008, 8, s. 35–44.
- 14 **Van Bortel, L. M. – Bulpitt, C. J. – Fici, F.:** Quality of life and antihypertensive effect with nebivolol and losartan. *Am J Hypertens*, 2005, 18, s. 1060–1066.
- 15 **Gungor, G., et al.:** Nebivolol protects erectile functions compared to metoprolol in hypertensive men with atherogenic, venogenic, psychogenic erectile dysfunction: A prospective, randomized, cross-over, clinical trial. *Eur J Intern Med*, 2022, 103, s. 69–75.
- 16 **Gur, O., et al.:** The comparison of the effects of nebivolol and metoprolol on erectile dysfunction in the cases with coronary artery bypass surgery. *Ann Thorac Cardiovasc Surg*, 2017, 23, s. 91–95.
- 17 **Fogari, R., et al.:** Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. *J Hum Hypertens*, 1997, 11, s. 753–757.
- 18 **Kaiser, T., et al.:** Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. *J Hypertens*, 2006, 24, s. 1397–403.
- 19 **Schmidt, A. C., et al.:** Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. *Clin Drug Investig*, 2007, 27, s. 841–849.
- 20 **Ladage, D., et al.:** Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. *J Cardiovasc Pharmacol*, 2010, 56, s. 275–281.
- 21 **Nodari, S. – Metra, M. – Dei Cas, L.:** Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. *Eur J Heart Fail*, 2003, 5, s. 621–627.
- 22 **Kampus, P., et al.:** Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. *Hypertension*, 2011, 57, s. 1122–1128.
- 23 **Wisnibaugh, T., et al.:** Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. *J Am Coll Cardiol*, 1993, 21, s. 1094–1100.
- 24 **Edes, I. – Gasior, Z. – Wita, Z.:** Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. *Eur J Heart Fail*, 2005, 7, s. 631–639.
- 25 **Flather, M.D., et al.:** Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*, 2005, 26, s. 215–225.
- 26 **The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II):** a randomised trial. *Lancet*, 1999, 353, s. 9–13.
- 27 **MERIT-HF Study Group:** Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*, 1999, 353, s. 2001–2007.
- 28 **Packer, M., et al.:** Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation*, 2002, 106, s. 2194–2199.
- 29 **Ghio, S., et al.:** Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. *Eur Heart J*, 2006, 27, s. 562–568.
- 30 **Grassi, G., et al.:** Multicenter randomized double-blind comparison of nebivolol plus HCTZ and irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients: results of the NEHS Study. *Adv Ther*, 2017, 33, s. 2173–2187.
- 31 **Malacco, E.:** Nebivolol/hydrochlorothiazide: a new fixed-dose combination for effective simplified antihypertensive therapy. *High Blood Press Cardiovasc Prev*, 2008, 15, s. 75–84.
- 32 **Malacco, E.:** Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients. *Eur Rev Med Pharmacol Sci*, 2010, 14, s. 427–434.

Použití landiololu u pacientky se srdečním selháním a supraventrikulární tachykardií – kazuistika

MUDr. Aneta Dvořáková Kardiologické oddělení, Nemocnice Na Homolce, Praha M

MUDr. Andreas Krüger, Ph.D. Kardiologické oddělení, vedoucí lékař, Nemocnice Na Homolce, Praha

- 1 **Fiala, M. – Haman, L. – Čihák, R.:** Doporučení ESC pro diagnostiku a léčbu fibrilace síní, 2020. Souhrn dokumentu připravený Českou kardiologickou společností. *Cor Vasa*, 2021, 63, s. 135–161.
- 2 **McKee, J. S. – Rabinow, B. E. – Daller, J. R., et al.:** An enantiomerically pure formulation of esmolol attenuates hypotension and preserves heart rate control in dogs. *Anesthesiology*, 2014, 121, s. 1184–1193.
- 3 **Krumpl, G. – Ulc, I. – Trebs, M., et al.:** Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group. *Eur J Clin Pharmacol*, 2017, 73, s. 417–428.
- 4 **Nasrollahi-Shirazi, S. – Susic, S. – Yang, Q., et al.:** Comparison of the beta-adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions. *J Pharmacol Exp Ther*, 2016, 359, s. 73–81.
- 5 **Domanovits, H. – Wolzt, M. – Stix, G.:** Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. *Eur Heart J Suppl*, 2018, 20, suppl. A, s. A1–A3.
- 6 **SPC Rapibloc:** www.sukl.cz.
- 7 **Dan, G.-A. – Dan, A. R. – Ivanescu, A., et al.:** Acute rate control in atrial fibrillation: an urgent need for the clinician. *Eur Heart J*, 2022, 44, suppl. D, s. D3–D10.
- 8 **Nagai, R. – Kinugawa, K. – Inoue, H., et al.:** Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-Land Study). *Circ J*, 2013, 77, s. 908–916.
- 9 **Yamashita, T. – Nakasu, Y. – Mizutani, H., et al.:** A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure – AF-CHF landiolol survey. *J Cardiol*, 2019, 74, s. 418–425.
- 10 **Kinugawa, K. – Nagai, R. – Inoue, H., et al.:** Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study (published correction appears in *Adv Ther*, 2014, 31, s. 577–578). *Adv Ther*, 2014, 31, s. 426–439.
- 11 **Syed, Y. Y.:** Landiolol: a review in tachyarrhythmias. *Drugs*, 2018, 78, s. 377–388.
- 12 **Shiga, T. – Ikeda, T. – Shimizu, W., et al.:** Efficacy and safety of landiolol in patients with ventricular tachyarrhythmias with or without renal impairment – subanalysis of the J-Land II Study. *Circ Rep*, 2020, 2, s. 440–445.
- 13 **Takahata, T. – Yasui-Furukori, N. – Sakamoto, J., et al.:** Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker. *Drugs R D*, 2005, 6, s. 385–394.
- 14 **Matsuda, N. – Nishida, O. – Taniguchi, T., et al.:** Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomised controlled study. *EclinicalMedicine*, 2020, 28, 100571.
- 15 **Tamura, T. – Yatabe, T. – Yokoyama, M.:** Prevention of atrial fibrillation after cardiac surgery using low-dose landiolol: A systematic review and meta-analysis. *J Clin Anesth*, 2017, 42, s. 1–6.
- 16 **European Heart Journal Supplements**, 2022, 24, suppl. D, s. D34–D42.

Arytmie v praxi – kazuistiky

MUDr. Marek Šramko, Ph.D., FESC IKEM, Praha

- 1 **Bezati, S. – Velliou, M. – Polyzogopoulou, E.**: The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature. *Eur Heart J Suppl*, 2022, 24, suppl. D, s. D22–D33
- 2 **Matsuda, N. – Nishida, O. – Taniguchi, T.**: Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: Subanalysis of the J-Land 3S randomized controlled study. *E Clinical Medicine*, 2020, 28, 100571.
- 3 **Kakihana, Y. – Nishida, O. – Taniguchi, T.**: Efficacy and safety of landiolol, an ultra-short-acting β 1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomized controlled trial. *Lancet Respir Med*, 2020, 8, s. 863–872.
- 4 **Hyndricks, G, et al.**: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*, 2021, 42, s. 373–498.
- 5 **Dabrowski, W. – Siwicka-Gieroba, D. – Piasek, E.**: Successful combination of landiolol and levosimendan in patients with decompensated heart failure. *Int Heart J*, 2020, 61, s. 384–389.

Role kardio-reno-metabolického syndromu v prevenci častých chronických onemocnění

prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, II. interní klinika LF UK a Fakultní nemocnice Plzeň

- 1 **Marassi, M. – Fadini, G. P.**: The cardio-renal-metabolic connection: a review of the evidence. *Cardiovasc Diabetol*, 2023, 22, s. 195.
- 2 **Ronco, C., et al.**: Cardio-renal syndrome. *JACC*, 2008, 52, s. 1527–1539.
- 3 **Alberti, K. G. – Eckel, R. H. – Grundy, S. M., et al.**: Harmonizing the metabolic syndrome: joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, 2009, 120, s. 1640–1645.
- 4 **Ndumele, Ch. E., et al.**: A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. *Circulation*, 2023, 148, s. 1636–1664.
- 5 **Devereux, R. B. – Roman, M. J. – Paranicas, M., et al.**: Impact of diabetes on cardiac structure and function: the strong heart study. *Circulation*, 2000, 101, s. 2271–2276.
- 6 **ADVANCE Collaborative Group**: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. *Lancet*, 2007, 370, s. 829–840.
- 7 **Zoungas, S. – Chalmers, J. – Neal, B., et al.**: Follow-up of blood pressure lowering and glucose control in type 2 diabetes. *N Engl J Med*, 2014, 371, s. 1392–1406.
- 8 **Chalmers, J. – Mourad, J. J. – Brzozowska-Villatte, R., et al.**: Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials. *J Hypertens*, 2023, 41, s. 508–515.
- 9 **Rosolova, H. – Mayer, O. Jr. – Reaven, G.**: Effect of variations in plasma magnesium concentration on resistance to insulin-mediated glucose disposal in nondiabetic subjects. *J Clin Endocrinol Metab*, 1997, 82, s. 3783–3785.

Postavení rivaroxabanu v dávce 2,5 mg v současné medicíně

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Kubitza, D. – Becka, M. – Voith, B., et al.**: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. *Clin Pharmacol Ther*, 2005, 78, s. 412–421.
- 2 **Graff, J. – Harder, S.**: Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. *Clin Pharmacokinet*, 2013, 52, s. 243–254.
- 3 **Kubitza, D. – Becka, M. – Wensing, G., et al.**: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. *Eur J Clin Pharmacol*, 2005, 61, s. 873–880.
- 4 **Xu, X. S. – Moore, K. – Burton, P., et al.**: Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. *Br J Clin Pharmacol*, 2012, 74, s. 86–97.
- 5 **Eikelboom, J. W. – Connolly, S. J. – Bosch, J., et al.**: Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med*, 2017, 377, s. 1319–1330.
- 6 **Steffel, J. – Eikelboom, J. W. – Anand, S. S., et al.**: The COMPASS Trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease. *Circulation*, 2020, 142, s. 40–48.
- 7 **Pogosova, N. – Bosch, J. – Bhatt, D. L., et al.**: Rivaroxaban 2.5 mg twice daily plus aspirin reduces venous thromboembolism in patients with chronic atherosclerosis. *Circulation*, 2022, 145, s. 1875–1877.
- 8 **Bonaca, M. P. – Bauersachs, R. M. – Anand, S. S., et al.**: Rivaroxaban in peripheral artery disease after revascularization. *N Engl J Med*, 2020, 382, s. 1994–2004.
- 9 **De Luca, L.**: Low-dose rivaroxaban: can cardiovascular events be reduced? *Eur Heart J Suppl*, 2023, 25, suppl. C, s. C20–C26.
- 10 **Mega, J. L. – Braunwald, E. – Mohanavelu, S., et al.**: Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. *Lancet*, 2009, 374, s. 29–38.
- 11 **Mega, J. L. – Braunwald, E. – Wiviott, S. D., et al.**: Rivaroxaban in patients with a recent acute coronary syndrome. *N Engl J Med*, 2012, 366, s. 9–19.
- 12 **Ohman, E. M. – Roe, M. T. – Steg, P. G., et al.**: Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. *Lancet*, 2017, 389, s. 1799–1808.
- 13 Úhradové podmínky přípravku Kardatuxan 2,5 mg. Dostupné z: www.sukl.cz, vyhledáno 20. 9. 2024.

Zkušenosti s canagliflozinem v běžné klinické praxi

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Zinman, B. – Wanner, C. – Lachin, J. M., et al.**: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.
- 2 **Neal, B. – Perkovic, V. – Mahaffey, K. W., et al.**: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 644–657.
- 3 **Wiviott, S. D. – Raz, I. – Bonaca, M. P., et al.**: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.
- 4 **Perkovic, V. – Jardine, M. J. – Neal, B., et al.**: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*, 2019, 380, s. 2295–2306.
- 5 **Rosenstock, J. – Aggarwal, N. – Polidori, D., et al.**: Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. *Diabetes Care*, 2012, 35, s. 1232–1238.
- 6 **Zaccardi, F. – Webb, D. R. – Htike, Z. Z., et al.**: Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. *Diabetes Obes Metab*, 2016, 18, s. 783–794.
- 7 **Gallwitz, B.**: The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors – real-world data. *Eur Endocrinol*, 2018, 14, s. 17–23.
- 8 **Gorgojo-Martínez, J. J. – Gargallo-Fernández, M. A. – Galdón Sanz-Pastor, A., et al.**: Real-world clinical outcomes associated with canagliflozin in patients with type 2 diabetes mellitus in Spain: The Real-WeCan Study. *J Clin Med*, 2020, 9, s. 2275.
- 9 **Gorgojo-Martínez, J. J. – Ferreira-Ocampo, P. J. – Galdón Sanz-Pastor, A., et al.**: Effectiveness and tolerability of the intensification of canagliflozin dose from 100 mg to 300 mg daily in patients with type 2 diabetes in real life: The INTENSIFY Study. *J Clin Med*, 2023, 12, s. 4248.

Optimalizace hemoglobinu v předoperační přípravě pacientů podstupujících implantaci totálních náhrad kyčelního a kolenního kloubu

MUDr. Vít Lorenc, MBA Anesteziologicko-resuscitační oddělení, Nemocnice Jindřichův Hradec, a. s.

- 1 **Muñoz, M. – Acheson, A. G. – Auerbach M., et al.**: International consensus statement on the peri-operative management of anaemia and iron deficiency. *Anaesthesia*, 2017, 72, s. 233–247.
- 2 **Cusack, B. – Buggy, D. J.**: Anaesthesia, analgesia, and the surgical stress response. *BJA Educ*, 2020, 20, s. 321–328.
- 3 **Baron, D. R. – Hochrieser, H. – Posch, M., et al.**: European Surgical Outcomes Study (EuSOS) group for Trials Groups of European Society of Intensive Care Medicine; European Society of Anaesthesiology: Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. *Br J Anaesth*, 2014, 113, s. 416–423.
- 4 **Muñoz, M. – Gómez-Ramírez, S. – Kozek-Langenecker, S., et al.**: 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. *Br J Anaesth*, 2015, 115, s. 15–24.
- 5 **Luo, X. – Li, F. – Hu, H., et al.**: Anemia and perioperative mortality in non-cardiac surgery patients: a secondary analysis based on a single-center retrospective study. *BMC Anesthesiol*, 2020, 20, s. 112.
- 6 **Rosencher, N. – Kerckamp, H. E. – Macheras, G., et al.**: Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. *Transfusion*, 2003.
- 7 **Jindal, P. – Patil, V. – Pradhan, R., et al.**: Update on preoperative

- evaluation and optimisation. *Indian J Anaesth*, 2023, 67, s. 39–47.
- Gelebo, K. G. – Neme, D. – Destaw, B., et al.: The effect of preoperative anemia on perioperative outcomes among patients undergoing emergency surgery: A multicenter prospective cohort study. *Heliyon*, 2023, 9, e17804.
 - Wainwright, T. W. – Gill, M. – McDonald, D. A., et al.: Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations. *Acta Orthop*, 2020, 91, s. 3–19.
 - Gustafsson, U. O. – Scott, M. J. – Hubner, M., et al.: Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. *World J Surg*, 2019, 43, s. 659–695.
 - Froessler, B. – Palm, P. – Weber, I., et al.: The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. *Ann Surg*, 2016, 264, s. 41–46.
 - Melloul, E. – Lassen, K. – Roulin, D., et al.: Guidelines for perioperative care for pancreatoduodenectomy: Enhanced Recovery After Surgery (ERAS) Recommendations 2019. *World J Surg*, 2020, 44, s. 2056–2084.

NAFLD – MAFLD – MASLD. Jak se vyznat ve zkratkách těchto onemocnění?

doc. MUDr. Lukáš Zlatohlávek, Ph.D. | MUDr. Jana Beňová Becherová

III. interní klinika – klinika endokrinologie a metabolismu, 1. LF UK a VFN, Praha

- Younossi, Z. M., et al.: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol*, 2018, 15, s. 11–20.
- Eslam, M., et al.: A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol*, 2020, 73, s. 202–209.
- Friedman, S. L., et al.: Mechanisms of NAFLD development and therapeutic strategies. *Nat Med*, 2018, 24, s. 908–922.
- Targher, G., et al.: The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. *Nat Rev Gastroenterol Hepatol*, 2021, 18, s. 599–612.
- Chalasan, N., et al.: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*, 2018, 67, s. 328–357.
- Eslam, M., et al.: MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterol*, 2020, 158, s. 1999–2014.e1.
- Tilg, H. – Moschen, A. R.: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology*, 2010, 52, s. 1836–1846.
- Byrne, C. D. – Targher, G.: NAFLD: a multisystem disease. *J Hepatol*, 2015, 62, suppl. 1, s. S47–64.

Terapie průjmů neinfekčního původu

PharmDr. MUDr. Vilma Vranová, Ph.D. Ústav aplikované farmacie, Farmaceutická fakulta MUNI, Brno

- SÚKL: Farmakoterapeutické informace SUKL 2011/4. Dostupné z: <https://www.sukl.cz/sukl/farmakoterapeutice-informace>, vyhledáno 26. 8. 2024.
- Mikolášek, P.: Dehydratace u dětí. *Pediatr Praxi*, 2018, 19, s. 252–255.
- Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře. Dostupné z: <https://www.svl.cz/files/files/Doporucene-postupy-od-2013/Akutni-prujem-u-dospelych.pdf>, vyhledáno 28. 8. 2024.
- SPC Lacidofil. Datum revize textu 4. 8. 2023.
- SPC Mutaflor. Datum revize textu 7. 12. 2011.
- SPC Enterol. Datum revize textu 22. 9. 2021.
- SPC Hylak. Datum první registrace / Proloužení registrace 6. 2. 2019 / 13. 2. 2024
- SPC Imodium. Datum revize textu 7. 12. 2011.
- Reasec 2,5 mg/0,025 mg tablety. Datum revize textu 6. 9. 2022.
- SPC Hidrasec. Datum první registrace / Proloužení registrace 14. 12. 2011.
- SPC Tasectan. Dle zkrácených informací zdravotnického prostředku.
- Ambrožová, H.: Pacient s průjmem v ordinaci praktického lékaře: příčiny a řešení. *Med Praxi*, 2021, 18, s. 236–242.

Biologická a cílená léčba u idiopatických střevních zánětů

prof. MUDr. Milan Lukáš, CSc., AGAF Klinické a výzkumné centrum pro idiopatické střevní záněty; Klinické centrum ISCARE, a. s.,

a 1. LF UK, Praha

- Lukáš, M., et al.: Biologická léčba. In: Milan Lukáš (ed.): *Pokroky v diagnostice a léčbě idiopatických střevních zánětů*. Galen, 2019.
- Bressler, B.: Is there an optimal sequence of biologic therapies for inflammatory bowel disease? *Ther Adv Gastroenterol*, 2023, 16, s. 1–12.
- Sandborn, W. J. – van Asche, G. – Reinisch, W., et al.: Adalimumab induces and maintains clinical remission in patients with moderate to severe ulcerative colitis. *Gastroenterology*, 2012, 142, s. 257–265.
- Feagan, B. J. – Rutgeerts, P. – Sands, B. E., et al.: Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*, 2013, 369, s. 699–710.
- Sandborn, W. J. – Feagan, B. J. – D’Haens, G., et al.: Ozanimod as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*, 2021, 389, s. 1280–1291.
- Sands, B. E. – Sandborn, W. J. – Panaccione, R., et al.: Ustekinumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*, 2019, 381, s. 1201–1214.
- Sandborn, W. J. – Su, C. – Sands, B. E., et al.: Tofacitinib as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*, 2017, 376, s. 1723–1736.
- Danesa, S. – Vermeire, S. – Zhou, W., et al.: Upadacitinib as induction and maintenance therapy for moderate to severe ulcerative colitis: results from three phase 3, multicentre, double blind, randomised trials. *Lancet*, 2022, 399, s. 2113–2118.
- D’Haens, G. – Dubinsky, M. – Kobayashi, T., et al.: Mirikizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*, 2023, 388, s. 2444–2455.
- Shehab, M. – Alrashed, F. – Alsayegh, A., et al.: Comparative efficacy of biologics and small molecules in ulcerative colitis: A systematic review and network meta-analysis. *Clin Gastro Hepatol*, 2024, doi: 10.1016/j.cgh.2024.07.033.
- Rutgeerts, P. – Van Asche, G. – Sandborn, W. J., et al.: Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. *Gastroenterology*, 2012, 142, s. 1102–1111.
- Danesa, S. – Sandborn, W. J. – Colombel, J. F., et al.: Endoscopic, radiologic and histologic healing with vedolizumab in patients with active Crohn’s disease. *Gastroenterology*, 2019, 157, s. 1007–1018.
- Rutgeerts, P. – Gasink, C. – Chan, D., et al.: Ustekinumab as induction and maintenance therapy for Crohn’s disease. *N Engl J Med*, 2016, 375, s. 1946–1960.
- Sands, B. E. – Irving, P. M. – Hoops, T., et al.: Ustekinumab versus adalimumab for induction and maintenance therapy in biologic naive patients with moderately to severely Crohn’s disease: multicentre, randomised, double-blind, parallel group, phase 3-b trial. *Lancet*, 2022, 399, s. 2200–2211.
- Ferrante, M. – Panaccione, R. – Baert, F., et al.: Risankizumab as maintenance therapy for moderate-to severe active Crohn’s disease. Results from multicentre, randomised, double-blind, placebo controlled, withdrawal phase-3 FORTIFY maintenance trial. *Lancet*, 2022, 399, s. 2031–2046.
- Sandborn, W. J. – Feagan, B. G. – Loftus, E. W., et al.: Efficacy and safety of upadacitinib in a randomized trials of patients with Crohn’s disease. *Gastroenterology*, 2020, 158, s. 2123–2138.e8.
- Bressler, B. – Yarur, A. – Silverberg, M. S., et al.: Vedolizumab and anti-tumor necrosis factor alpha real world outcomes in biologic naive inflammatory bowel disease patients: Results from the EVOLVE study. *J Crohn’s Colitis*, 2021, 15, s. 1694–1706.

Diferenciální diagnostika intersticiálních plicních procesů pro praxi

doc. MUDr. Martina Šterclová, Ph.D. Pneumologická klinika, 2. LF UK a FN v Motole; Pneumologická klinika, 1. LF UK a FTN, Praha

- Todd, N. W. – Atamas, S. P. – Hines, S. E., et al.: Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease. *Expert Rev Respir Med*, 2022, 16, s. 235–245.
- Carbone, R. G. – Puppo, F. – Mattar, E., et al.: Acute and chronic eosinophilic pneumonia: an overview. *Front Med*, 2024, 11, 1355247.
- Hamblin, M. – Prosch, H. – Vašáková, M.: Diagnosis, course and management of hypersensitivity pneumonitis. *Eur Respir Rev*, 2022, 31, 210169.
- Hallowell, R. W. – Danoff, S. K.: Diagnosis and management of myositis-associated lung disease. *Chest*, 2023, 163, s. 1476–1491.
- Mukhopadhyay, S. – Parambil, J. G.: Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS). *Semin Respir Crit Care Med*, 2012, 33, s. 476–485.
- Raghu, G. – Meyer, K. C.: Cryptogenic organising pneumonia: current understanding of an enigmatic lung disease. *Eur Respir Rev*, 2021, 30, 210094.
- Valeyre, D. – Brauner, M. – Bernaudin, J. F., et al.: Differential diagnosis of pulmonary sarcoidosis: a review. *Front Med*, 2023, 10, 1150751.
- Woloszczak, J. – Wrześniewska, M. – Hrapkowicz, A., et al.: Comprehensive outlook on pulmonary alveolar proteinosis—a review. *Int J Mol Sci*, 2024, 25, s. 7092.

Co nového v pneumologii

doc. MUDr. Kristián Brat, Ph.D. Klinika nemocí plicních a tuberkulózy, LF MU a FN Brno

MUDr. Monika Bratová, Ph.D. Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno; LF MU, Brno

- Global Initiative for Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2024 Report. Dostupné z: <https://goldcopd.org/2024-gold-report/>, vyhledáno: 6. 9. 2024.
- Wan, E. S.: The clinical spectrum of PRISM. *Am J Respir Crit Care Med*, 2022, 206, s. 524–525.
- Webber, E. M. – Lin, J. S. – Thomas, R. G.: Screening for chronic obstructive pulmonary disease: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*, 2022, 327, s. 1812–1816.
- de Koning, H. J. – van der Aalst, C. M. – de Jong P. A., et al.: Reduced lung-cancer mortality with volume CT screening in a randomized trial. *N Engl J Med*, 2020, 382, s. 503–513.
- Brat, K. – Kouřil, J. – Hejduk, K., et al.: Projekt Časný záchyt chronické obstrukční plicní nemoci v rizikové populaci – jaké jsou průběžné výsledky? *Stud Pneumol Phthiseol*, 2022, 82, s. 42–49.
- Zatloukal, J. – Brat, K. – Neumannová, K., et al.: Chronická obstrukční plicní nemoc – diagnóza a léčba stabilní nemoci; personalizovaný přístup k péči, využívající koncept léčitelných charakteristik, založený na klinických fenotypech. *Stud Pneumol Phthiseol*, 2023, 83, s. 45–80.
- Bhatt, S. P. – Rabe, K. F. – Hanania, N. A., et al.: NOTUS Study Investigators: Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. *N Engl J Med*, 2024, 390, s. 2274–2283.
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Dostupné z: <https://ginasthma.org/2024-report/>, vyhledáno: 4. 9. 2024.
- Roberts, M. E. – Rahman, N. M. – Maskell, N. A., et al.: British Thoracic Society Guideline for pleural disease. *Thorax*, 2023, 78, s. 1143–1156.
- Marinelli, D. – Gallina, F. T. – Pannunzio, S., et al.: Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials. *Crit Rev Oncol Hematol*, 2023, 192, 104190.
- Forde, P. M. – Spicer, J. – Lu, S., et al.: CheckMate 816 Investigators: Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. *N Engl J Med*, 2022, 386, s. 1973–1985.
- Úhradové podmínky OPDIVO, SÚKL, dostupné z: https://prehledy.sukl.cz/prehled_liciv.html#/liciva/0255268, vyhledáno: 4. 9. 2024.
- Wu, Y. L. – Dziadziuszko, R. – Ahn, J. S., et al.: Alectinib in resected ALK-positive non-small-cell lung cancer. *N Engl J Med*, 2024, 390, s. 1265–1276.
- Solomon, B. J. – Bauer, T. M. – Mok, T. S. K., et al.: Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. *Lancet Respir Med*, 2023, 11, s. 354–366.
- Zhou, C. – Tang, K. J. – Cho, B. C., et al.: PALLON Investigators: Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. *N Engl J Med*, 2023, 389, s. 2039–2051.
- Wallenfels, J.: Epidemiologická situace TBC v České republice v roce 2023. *Stud Pneumol Phthiseol*, 2024, 84, s. 25–27.

Nová antiobezitika

prof. MUDr. Štěpán Svačina, DrSc., MBA III. interní klinika, 1. LF UK a VFN, Praha

- Svačina, Š.: *Antiobezitika – vývoj, současnost a perspektivy*. Praha, Grada Publishing, 2022.
- Svačina, Š.: *Antidiabetika – historie, současnost a budoucnost*. Praha, Axonite, 2016.
- Svačina, Š.: Tirzepatid jako posel budoucnosti – nové antidiabetikum se širokými perspektivami. *Aktuální medicína*, 2023, 7, s. 43–48.
- Andraos, J. – Muhar, H. – Smith, S. R.: Beyond glycaemia: Comparing tirzepatid to GLP-1 analogues. *Rev Endocr Metab Disord*, 2023, 24, s. 1089–1101.
- Forzano, I., et al.: Tirzepatid: a systematic update. *Int J Mol Sci*, 2022, 23, s. 14631.
- Rosenstock, J., et al.: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatid in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet*, 2021, 398, s. 143–155.
- Friás, J. P., et al.: Tirzepatid versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2 study). *N Engl J Med*, 2021, 385, s. 503–515.
- Del Prato, S., et al.: Tirzepatid versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *JAMA*, 2022, 327, s. 534–545.
- Jastreboff, A. M., et al.: Tirzepatid once weekly for the treatment of obesity. SURMOUNT-1 Study. *N Engl J Med*, 2022, 387, s. 205–216.
- Aronne, L. J. – Sattar, N. – Horn, D. B., et al.: Continued treatment with tirzepatid for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. *JAMA*, 2024, 331, s. 38–48.
- Svačina, Š.: Farmakologická léčba obezity a snížení TK. In: Widimský, J. (ed.): *Arteriální hypertenze – současné klinické trendy. XXI. symposium – sborník*. Praha, Triton, 2024.
- Yao, H., et al.: Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. *BMJ*, 2024, 384, s. e076410.
- Sun, X., et al.: Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy. *Peptides*, 2024, 177, 171203.

Antidiabetika v ordinaci internisty

prof. MUDr. Milan Kvapil, CSc., MBA | MUDr. Martina Nováková Geritrická interní klinika, 2. LF UK a FN v Motole, Praha

- Maruthur, N. M. – Tseng, E. – Hutless, S., et al.: Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. *Ann Intern Med*, 2016, 164, s. 740–751.
- Richter, B. – Bandeira-Echtler, E. – Bergerhoff, K., et al.: Pioglitazone for type 2 diabetes mellitus. *Cochrane Database Syst Rev*, 2006, 2006, CD006060.
- Karásek, D.: Pioglitazone. *Vnitřní lékařství*, 2020, 66, s. 121–125.
- Mishriky, B. M. – Cummings, D. M. – Tanenberg, R. J.: The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. *Diabetes Res Clin Pract*, 2015, 109, s. 378–388.
- Deacon, C. F.: Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol*, 2020, 16, s. 642–653.
- Nauck, M. A. – Quast, D. R. – Wefers, J., et al.: GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. *Mol Metab*, 2021, 46, 101102.
- Yao, H. – Zhang, A. – Li, D., et al.: Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. *BMJ*, 2024, 384, e076410.
- Eng, C. – Kramer, C. K. – Zinman, B., et al.: Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. *Lancet*, 2014, 384, s. 2228–2234.
- Wright, E. M.: SGLT2 inhibitors: physiology and pharmacology. *Kidney360*, 2021, 2, s. 2027–2037.
- Marilly, E. – Cottin, J. – Cabrera, N., et al.: SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. *Diabetologia*, 2022, 65, s. 2000–2010.
- Groop, L. C.: Sulfonylureas in NIDDM. *Diabetes Care*, 1992, 15, s. 737–754.
- Lv, W. – Wang, X. – Xu, Q. – Lu, W.: Mechanisms and characteristics of sulfonylureas and glinides. *Curr Top Med Chem*, 2020, 20, s. 37–56.
- Black, C. – Donnelly, P. – McIntyre, L., et al.: Meglitinide analogues for type 2 diabetes mellitus. *Cochrane Database Syst Rev*, 2007, 2007, CD004654.
- Drake, T. – Landsteiner, A. – Langsetmo, L., et al.: Newer pharmacologic treatments in adults with type 2 diabetes: A systematic review and network meta-analysis for the American College of Physicians. *Ann Intern Med*, 2024, 177, s. 618–632.

Klinické projevy chronické hypotyreózy

MUDr. Karolína Drbalová | MUDr. Mikuláš Kosák, Ph.D. | MUDr. Monika Nývltová

Interní klinika 1. LF UK a Ústřední vojenské nemocnice – Vojenské fakultní nemocnice, Praha

- Yoo, W. S. – Chung, H. K.: Subclinical hypothyroidism: prevalence, health impact, and treatment landscape. *Endocrinol Metab*, 2021, 36, s. 500–513.
- Klein, I. – Ojamaa, K.: Thyroid hormone and the cardiovascular system. *N Engl J Med*, 2001, 344, s. 501–509.
- Tribulova, N. – Knezl, V. – Shainberg, A., et al.: Thyroid hormones and cardiac arrhythmias. *Vascul Pharmacol*, 2010, 52, s. 102–112.
- Razvi, S. – Weaver, J. U. – Vanderpump, M. P., et al.: The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. *J Clin Endocrinol Metab*, 2010, 95, s. 1734–1740.
- Boekholdt, S. M. – Titan, S. M. – Wiersinga, W. M., et al.: Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. *Clin Endocrinol*, 2010, 72, s. 404–410.
- Rodondi, N. – den Elzen, W. P. J. – Bauer, D. C., et al.: Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA*, 2010, 304, s. 1365–1374.
- Cooper, D. S. – Biondi, B.: Subclinical thyroid disease. *Lancet Lond Engl*, 2012, 379, s. 1142–1154.
- Kahaly, G. J.: Polyglandular autoimmune syndromes. *Eur J Endocrinol*, 2009, 161, s. 11–20.
- Singh, G. – Jialal, I.: Polyglandular Autoimmune Syndrome Type II. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. Dostupné z: <https://www.ncbi.nlm.nih.gov/books/NBK525992/>, vyhledáno 26. 8. 2024.
- Jabbar, A. – Pingitore, A. – Pearce, S. H. S., et al.: Thyroid hormones and cardiovascular disease. *Nat Rev Cardiol*, 2017, 14, s. 39–55.
- Al-Janabi, G. – Hassan, H. N. – Al-Fahham, A.: Biochemical changes in patients during hypothyroid phase after thyroidectomy. *J Med Life*, 2022, 15, s. 104–108.
- Treister-Goltzman, Y. – Yarza, S. – Peleg, R.: Lipid profile in mild subclinical hypothyroidism: systematic review and meta-analysis. *Minerva Endocrinol*, 2021, 46, s. 428–440.
- Liu, J. – Chen, Y. – Ren, B., et al.: Alteration of lipid profile between subclinical hypothyroidism and well-matched controls: a meta-analysis. *Horm Metab Res*, 2023, 55, s. 479–486.
- Hána, V.: *Endokrinologie pro praxi*. Maxdorf, 2019.
- Klein, I. – Danzi, S.: Thyroid disease and the heart. *Circulation*, 2007, 116, s. 1725–1735.

Stabilizace hladiny TSH u pacientky s autoimunitní tyreoiditidou – kazuistika

MUDr. Tereza Grimmichová Endokrinologický ústav, Praha, Interní klinika, FN Královské Vinohrady a 3. LF UK, Praha

- 1 Brito, J. P. – Deng, Y. – Ross, J. S., et al.: Association between generic-to-generic levothyroxine switching and thyrotropin levels among US adults. *JAMA Intern Med*, 2022, 182, s. 418–425.
- 2 Jonklaas, J. – Bianco, A. C. – Bauer, A. J., et al.: American Thyroid Association Task Force on Thyroid Hormone Replacement: Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid*, 2014, 24, s. 1670–1751.
- 3 Pabla, D. – Akhlaghi, F. – Zia, H.: A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. *Eur J Pharm Biopharm*, 2009, 72, s. 105–110.
- 4 Santaguida, M. G. – Virili, C. – Del Duca, S. C., et al.: Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. *Endocrine*, 2015, 49, s. 51–57.
- 5 Trimboli, P. – Virili, C. – Centanni, M., et al.: Thyroxine treatment with softgel capsule formulation: usefulness in hypothyroid patients without malabsorption. *Front Endocrinol*, 2018, 9, s. 118.
- 6 Virili, C. – Giovannella, L. – Fallahi, P., et al.: Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation, a systematic review and meta-analysis. *Front Endocrinol*, 2018, 9, s. 10.
- 7 Vita, R. – Saraceno, G. – Trimarchi, F., et al.: A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. *Endocrine*, 2013, 43, s. 154–160.

Hořčík a stres – circulus vitiosus...

MUDr. Jarmila Křížová, Ph.D. III. interní klinika, 1. LF UK a VFN, Praha

- 1 Boyle, N. B. – Lawton, C. – Dye, L.: The effects of magnesium supplementation on subjective anxiety and stress—a systematic review. *Nutrients*, 2017, 9, s. 429.
- 2 Serefko, A. – Szopa, A. – Poleszak, E.: Magnesium and depression. *Magnes Res*, 2016, 29, s. 112–119.
- 3 Noah, L. – Dye, L. – Bois De Fer, B., et al.: Effect of magnesium and vitamin B₆ supplementation on mental health and quality of life in stressed healthy adults: Post-hoc analysis of a randomised controlled trial. *Stress Health*, 2021, 37, s. 1000–1009.
- 4 Pouteau, E. – Kabir-Ahmadi, M. – Noah, L., et al.: Superiority of magnesium and vitamin B6 over magnesium alone on severe stress in healthy adults with low magnesium: A randomized, single-blind clinical trial. *PLoS One*, 2018, 13, e0208454.
- 5 Noah, L. – Morel, V. – Bertin, C., et al.: Effect of a combination of magnesium, B vitamins, rhodiola, and green tea (L-theanine) on chronically stressed healthy individuals—a randomized, placebo-controlled study. *Nutrients*, 2022, 14, s. 1863.
- 6 Noah, L. – Pickering, G. – Mazur, A., et al.: Impact of magnesium supplementation, in combination with vitamin B6, on stress and magnesium status: secondary data from a randomized controlled trial. *Magnes Res*, 2020, 33, s. 45–57.
- 7 Arab, A. – Rafie, N. – Amani, R., et al.: The role of magnesium in sleep health: a systematic review of available literature. *Biol Trace Elem Res*, 2023, 201, s. 121–128.

Klinická doporučení v prevenci a léčbě dekubitů – v kontextu základních ošetřovatelských intervencí

prof. PhDr. Andrea Pokorná, Ph.D. Ústav zdravotnických věd, Lékařská fakulta, Masarykova univerzita, Brno

- 1 Pokorná, A. – Benešová, K. – Jarkovský, J., et al.: Pressure injuries in inpatient care facilities in the Czech Republic. Analysis of a national electronic database. *J Wound Ostomy Continence Nurs*, 2017, 44, s. 1–5.
- 2 Bůřilová, P. – Pokorná, A. – Benešová, K., et al.: A ten-year follow-up of the prevalence of pressure injuries in the Czech Republic: Analysis of the National Registry. *Int Wound J*, 2022, 19, s. 1870–1877.
- 3 Sen, C. K. – Gordillo, G. M. – Roy, S., et al.: Human skin wounds: a major and snowballing threat to public health and the economy. *Wound Repair Regen*, 2009, 17, s. 763–771.
- 4 European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. In: Haesler, E. (ed.): Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. *The International Guideline*. EPUAP/NPIAP/PPPIA; 2019.
- 5 Pokorná, A. – Leaper, D.: Assessment and documentation of nonhealing, chronic wounds in inpatient health care facilities in The Czech Republic: an evaluation study. *Int Wound J*, 2015, 12, s. 224–231.
- 6 Moore, Z. – Avsar, P. – Conaty, L., et al.: The prevalence of pressure ulcers in Europe, what does the European data tell us: a systematic review. *J Wound Care*, 2019, 28, s. 710–719.
- 7 Al-Otaibi, Y. K. – Al-Nowaiser, N. – Rahman, A.: Reducing hospital-acquired pressure injuries. *BMJ Open Quality*, 2019, 8, e000464.
- 8 Pokorná, A. – Dolanová, D. – Benešová, K., et al.: How the COVID-19 pandemic influences the prevalence of pressure injuries in the Czech Republic: A nationwide analysis of a health registry in 2020. *J Tissue Viability*, 2022, 31, s. 424–430.
- 9 Dolanová, D. – Bůřilová, P. – Krupová, L., et al.: Mortality related to pressure ulcers in Czech Republic – analyses of national health registries. *J Tissue Viability*, 2023, 32, s. 365–370.
- 10 Guyatt, G. H. – Oxman, A. D. – Kunz, R., et al.: What is „quality of evidence“ and why is it important to clinicians? *BMJ*, 2008, 336, s. 995–998.
- 11 Guyatt, G. H. – Oxman, A. D. – Vist, G. E., et al.: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008, 336, s. 924–926.
- 12 Guyatt, G. – Oxman, A. D. – Akl, E. A., et al.: GRADE guidelines: 1. Introduction–GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*, 2011, 64, s. 383–394.
- 13 Duimel-Peeters, I. – Halfens, R. – Ambergen, A., et al.: The effectiveness of massage with and without dimethyl sulfoxide in preventing pressure ulcers: A randomized, double-blind cross-over trial in patients prone to pressure ulcers. *Int J Nurs Stud*, 2007, 44, s. 1285–1295.
- 14 Duimel-Peeters, I. – Halfens, R. – Berger, P., et al.: The effects of massage as a method to prevent pressure ulcers. A review of the literature. *Ostomy Wound Manage*, 2005, 51, s. 70–80.
- 15 Black, J. – Alves, P. – Brindle, C. T., et al.: Use of wound dressings to enhance prevention of pressure ulcers caused by medical devices. *Int Wound J*, 2015, 12, s. 322–327.
- 16 Mody, L. – Greene, M. T. – Meddings, J., et al.: A national implementation project to prevent catheter-associated urinary tract infection in nursing home residents. *JAMA Intern Med*, 2017, 177, s. 1154–1162.
- 17 Pokorná, A. – Strombachová, A. – Bůřilová, P., et al.: Využití pomůcek k managementu moči a stolice u hospitalizovaných pacientů jako možná příčina nežádoucí imobilizace. *Česká a slovenská neurologie a neurochirurgie*, 2022, 85, s. 28–33.
- 18 Verdú, J. – Soldevilla, J.: IPARZINE-SKR study: randomized, double-blind clinical trial of a new topical product versus placebo to prevent pressure ulcers. *Int Wound J*, 2012, 9, s. 557–565.
- 19 Lupianez-Perez, J. – Uttumchandani, S. K. – Morilla-Herrera, J. C., et al.: Topical olive oil is not inferior to hyperoxygenated fatty acids to prevent pressure ulcers in high-risk immobilised patients in home care. Results of a multicentre randomised triple-blind controlled non-inferiority trial. *PLoS One*, 2015, 10.
- 20 Aloweni, F. – Lim, M. L. – Chua, T. L., et al.: A randomised controlled trial to evaluate the incremental effectiveness of a prophylactic dressing and fatty acids oil in the prevention of pressure injuries. *Wound Pract Res*, 2017, 25, s. 24–34.
- 21 Francis, K. – ManPang, S. – Cohen, B., et al.: Disposable versus reusable absorbent underpads for prevention of hospital-acquired incontinence associated dermatitis and pressure injuries. *J Wound Ostomy Continence Nurs*, 2017, 44, s. 374–379.
- 22 Teerawattananon, Y. – Anothaisintawee, T. – Tantivess, S., et al.: Effectiveness of diapers among people with chronic incontinence in Thailand. *Int J Technol Assess Health Care*, 2015, 31, s. 249–255.
- 23 Smith, A. – McNichol, L. L. – Amos, M. A., et al.: A retrospective, non-randomized, before and after study of the effect of linens constructed of synthetic silk-like fabric on pressure ulcer incidence. *Ostomy Wound Manage*, 2013, 59, s. 28–34.
- 24 Freeman, R. – Smith, A. – Dickinson, S., et al.: Specialty linens and pressure injuries in high-risk patients in the intensive care unit. *Am J Crit Care*, 2017, 26, s. 474–481.
- 25 Smith, G. – Ingram, A.: Clinical and cost effectiveness evaluation of low friction and shear garments. *J Wound Care*, 2010, 19, s. 535–542.

Novinky v léčbě HIV a pozitivní dopad na prognózu pacientů

doc. MUDr. Svatava Snopková, Ph.D. | prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob, LF MU a FN Brno-Bohunice

- 1 Dominick, L. – Midgley, N. – Swart, L. M., et al.: HIV-related cardiovascular diseases: the search for a unifying hypothesis. *Am J Physiol Heart Circ Physiol*, 2020, 318, s. H731–H746.
- 2 Perkins, M. V. – Joseph, S. B. – Dittmer, D. P., et al.: Cardiovascular disease and thrombosis in HIV infection. *Arterioscler Thromb Vasc Biol*, 2023, 43, s. 175–191.
- 3 Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 27. 2. 2024. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC); dostupné z: <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new>, vyhledáno 17. 8. 2024.
- 4 Chen, J. – Zhou, T. – Zhang, Y., et al.: The reservoir of latent HIV. *Front Cell Infect Microbiol*, 2022, 12, 945956, doi: 10.3389/fcimb.2022.945956.
- 5 Global HIV programme. HIV data and statistics. World Health Organization; dostupné z: <https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics>, vyhledáno 17. 8. 2024.
- 6 Van Welzen, B. J. – Oomen, P. G. A. – Hoepelman, A. I. M.: Dual antiretroviral therapy – all quiet beneath the surface? *Front Immunol*, 2021, 12, 637910, doi: 10.3389/fimmu.2021.637910.
- 7 Steven, S. – Frenis, K. – Oelze, M., et al.: Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. *Oxid Med Cell Longev*, 2019, 2019, 7092151.
- 8 Teer, E. – Dominick, L. – Mukonowenzou, N. C., et al.: HIV-related myocardial fibrosis: inflammatory hypothesis and crucial role of immune cells dysregulation. *Cells*, 2022, 11, s. 2825.
- 9 Liu, R. – Simonetti, F. R. – Ho, Y. C.: The forces driving clonal expansion of the HIV-1 latent reservoir. *Viral J*, 2020, 17, s. 4.
- 10 Hong, F. F. – Mellors, J. W.: Changes in HIV reservoirs during long-term antiretroviral therapy. *Curr Opin HIV AIDS*, 2015, 10, s. 43–48.
- 11 Paiardini, M. – Dhodapkar, K. – Harper, J., et al.: Editorial: HIV and cancer immunotherapy: similar challenges and converging approaches. *Front Immunol*, 2020, 11, s. 519.
- 12 Henderson, L. J. – Reoma, L. B. – Kovacs, J. A., et al.: Advances toward curing HIV-1 infection in tissue reservoirs. *J Virol*, 2020, 94, e00375-19.
- 13 Cao, S. – Woodrow, K. A.: Nanotechnology approaches to eradicating HIV reservoirs. *Eur J Pharm Biopharm*, 2019, 138, s. 48–63.
- 14 Margolis, D. M. – Archin, N. M. – Cohen, M. S., et al.: Curing HIV: seeking to target and clear persistent infection. *Cell*, 2020, 181, s. 189–206.
- 15 Ahlenstiel, C. L. – Symonds, G. – Kent, S. J., et al.: Block and lock HIV cure strategies to control the latent reservoir. *Front Cell Infect Microbiol*, 2020, 10, s. 424.
- 16 Ait-Ammar, A. – Kula, A. – Darcis, G., et al.: Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. *Front Microbiol*, 2020, 10, s. 3060.
- 17 Grau-Expósito, J. – Luque-Ballesteros, L. – Navarro, J., et al.: Latency reversal agents affect differently the latent reservoir present in distinct

- CD4+ T subpopulations. *PLoS Pathog*, 2019, 15, e1007991.
- Peterson, T. A. – MacLean, A. G.: Current and future therapeutic strategies for lentiviral eradication from macrophage reservoirs. *Neuroimmunopharmacol*, 2019, 14, s. 68–93.
 - Lu, D. Y. – Wu, H. Y. – Yarla, N. S., et al.: HAART in HIV/AIDS treatment: future trends. *Infect Disord Drug Targets*, 2018, 18, s. 15–22.
 - Cao, S. – Woodrow, K. A.: Nanotechnology approaches to eradicating HIV reservoirs. *Eur J Pharm Biopharm*, 2019, 138, s. 48–63.
 - Thouelle, P. – Choong, E. – Cavasini, M., et al.: Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. *J Antimicrob Chemother*, 2022, 77, s. 290–302.
 - Oti, V. B.: Nanoparticles and its implications in HIV/AIDS therapy. *Curr Drug Discov Technol*, 2020, 17, s. 448–556.
 - Patil, V. – Patel, A.: Biodegradable nanoparticles: a recent approach and applications. *Current Drug Targets*, 2020, 21, s. 1722–1732.
 - Thouelle, P. – Choong, E. – Cavasini, M., et al.: Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. *J Antimicrob Chemother*, 2022, 77, s. 290–302.
 - Patil, V. – Patel, A.: Biodegradable nanoparticles: a recent approach and applications. *Current Drug Targets*, 2020, 21, s. 1722–1732.
 - Kevadiya, B. D. – Ottemann, B. – Mukadam, I. Z., et al.: Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. *Theranostics*, 2020, 10, s. 630–656.
 - Soriano, V. – Fernandez-Montero, J. V. – Benitez-Gutierrez, L., et al.: Dual antiretroviral therapy for HIV infection. *Expert Opin Drug Saf*, 2017, 16, s. 923–932.
 - Cutrell, A. G. – Schapiro, J. M. – Perno, C. F., et al.: Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. *AIDS*, 2021, 35, s. 1333–1342.
 - Overton, E. T. – Richmond, G. – Rizzardini, G., et al.: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. *Clin Infect Dis*, 2023, 76, s. 1646–1654.
 - Nachega, J. B. – Scarsi, K. K. – Gandhi, M., et al.: Long-acting antiretrovirals and HIV treatment adherence. *Lancet HIV*, 2023, 10, s. e332–e342.
 - Trivedi, J. – Mahajan, D. – Jaffe, R. J., et al.: Recent advances in the development of integrase inhibitors for HIV treatment. *Curr HIV/AIDS Rep*, 2020, 17, s. 63–75.
 - Cambou, M. C. – Landovitz, R. J.: Novel antiretroviral agents. *Curr HIV/AIDS Rep*, 2020, 17, s. 118–124.
 - Margot, N. – Ram, R. – Rhee, M., et al.: Absence of lenacapavir (GS-6207) phenotypic resistance in HIV Gag cleavage site mutants and in isolates with resistance to existing drug classes. *Antimicrob Agents Chemother*, 2021, 65, e02057–20.
 - Dvory-Sobol, H. – Shaik, N. – Callebaut, C., et al.: Lenacapavir: a first-in-class HIV-1 capsid inhibitor. *Curr Opin HIV AIDS*, 2022, 17, s. 15–21.
 - Menéndez-Arias, L. – Delgado, R.: Update and latest advances in antiretroviral therapy. *Trends Pharmacol Sci*, 2022, 43, s. 16–29.
 - Barin, F. – Stefic, K.: Anticorps neutralisants tri-spécifiques. Une solution pour l'immunoprophylaxie ou l'immunothérapie anti-VIH ? *Med Sci*, 2018, 34, s. 109–128.
 - Wang, Q. – Zhang, L.: Broadly neutralizing antibodies and vaccine design against HIV-1 infection. *Front Med*, 2020, 14, s. 30–42.
 - Haynes, B. F. – Burtzon, D. R. – Mascola, J. R.: Multiple roles for HIV broadly neutralizing antibodies. *Sci Transl Med*, 2019, 11, 516.eaaz2686.
 - Liu, Y. – Cao, W. – Sun, M., et al.: Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. *Emerg Microbes Infect*, 2020, 9, s. 194–206.
 - Dufloo, J. – Planchais, C. – Frémont, S., et al.: Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. *Nat Commun*, 2022, 13, s. 630.
 - Cao, S. – Woodrow, K. A.: Nanotechnology approaches to eradicating HIV reservoirs. *Eur J Pharm Biopharm*, 2019, 138, s. 48–63.
 - Frattari, G. S. – Caskey, M. – Sogaard, O. S.: Broadly neutralizing antibodies for HIV treatment and cure approaches. *Curr Opin HIV AIDS*, 2023, 18, s. 157–163.

Farmakoterapie v těhotenství

doc. MUDr. Michal Koucký, Ph.D. Klinika gynekologie, porodnictví a neonatologie, 1. LF UK a VFN, Praha

- Nilsen, K. – Staff, A. C. – Krogsrud, S. K.: Paracetamol use in pregnancy: Not as safe as we may think? *Acta Obstet Gynecol Scand*, 2023, 102, s. 652–656.
- Barańska, A. – Kanadys, W. – Wdowiak, A., et al.: Effects of prenatal paracetamol exposure on the development of asthma and wheezing in childhood: a systematic review and meta-analysis. *J Clin Med*, 2023, 12, s. 1832
- Rolnik, D. L. – Wright, D. – Poon, L. C. Y., et al.: ASPRE trial: performance of screening for preterm pre-eclampsia. *Ultrasound Obstet Gynecol*, 2017, 50, s. 492–495.
- Yu, P. A. – Tran, E. L. – Parker, C. M., et al.: Safety of antimicrobials during pregnancy: a systematic review of antimicrobials considered for treatment and postexposure prophylaxis of plague. *Clin Infect Dis*, 2020, 70, suppl. 1, s. S37–S50.
- Merlob, P. – Stahl, B. – Kaplan, B.: Drug use in pregnancy and breastfeeding: the role of the pharmacist. *Int J Risk Safety Med*, 1998, 11, s. 45–47.
- Zhu, Y. – Bateman, B. T. – Gray, K. J., et al.: Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. *BMJ*, 2020, 369, m1494.
- Peterka, M.: Vitamin A a nebezpečí vzniku vrozených vad u člověka. *Zdrav Nov*, 1996, 45, s. 9.
- Gregor, V.: Teratogenní rizika v graviditě. *Prakt Gynekol*, 2001, 3, s. 37–40.
- Šipek, A. – Gregor, V. – Velebil, P., et al.: Výskyt vrozených vad u dětí v potomstvu matek užívajících v I. trimestru gravidity medikaci v České republice v období 1996–2002. *Supplementum*, 2004, 1, s. 33–41.
- Grundmann, M.: Změny farmakokinetiky v těhotenství a jejich klinický význam. *Int Med Prax*, 2000, 3, s. 47–48.
- Syme, M. R. – Paxton, J. W. – Keelan, J. A.: Drug transfer and metabolism by the human placenta. *Clin Pharmacokinet*, 2004, 43, s. 487–514.
- Briggs, G. G. – Freeman, R. K. – Yaffe, S. J.: *Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk*. 11. vydání, Williams & Wilkins, 2017.
- Koucký, M.: „Banální“ léky v těhotenství. *Moderní Gynekol Porod*, 2004, 2, s. 167–173.
- Koucký, M. – Čepický, P.: Farmakoterapie v těhotenství. *Moderní Gynekol Porod*, 2003, 2, s. 278–284.
- Hořínová, V.: Farmakoterapie v těhotenství z pohledu klinického genetika. *Moderní Gynekol Porod*, 2004, 2, s. 156–166.
- Grundmann, M.: Změny farmakokinetiky v těhotenství a jejich klinický význam II. *Int Med Prax*, 2000, 4, s. 43–44.

Sarkopenie a sarkopenická obezita u seniorů

MUDr. Darina Matvejeva Geriatrická interní klinika, 2. LF UK a FN v Motole, Praha

- Brooks, S. V.: Current topics for teaching skeletal muscle physiology. *Adv Physiol Educ*, 2003, 27, s. 171–182.
- Lieber, R. L. – Ward, S. R.: Skeletal muscle design to meet functional demands. *Philos Trans R Soc Lond B Biol Sci*, 2011, 366, s. 1466–1476.
- Cruz-Jentoft, A. J. – Bahat, G. – Bauer, J., et al.: Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWG-SOP2), and the Extended Group for EWG-SOP2: Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*, 2019, 48, s. 16–31.
- Topinková, E.: Sarcopenia as a severe organ failure, its diagnosing and present therapeutic possibilities. *Vnitř Lek*, 2018, 64, s. 1038–1052.
- Cho, M. R. – Lee, S. – Song, S. K.: A review of sarcopenia pathophysiology, diagnosis, treatment and future direction. *J Korean Med Sci*, 2022, 37, s. e146.
- Papadopoulos, S. K.: Sarcopenia: a contemporary health problem among older adult populations. *Nutrients*, 2020, 12, s. 1293.
- Sayer, A. A. – Syddall, H. – Martin, H., et al.: The developmental origins of sarcopenia. *J Nutr Health Aging*, 2008, 12, s. 427–432.
- Bilski, J. – Pierzchalski, P. – Szczepanik, M., et al.: Multifactorial mechanism of sarcopenia and sarcopenic obesity. Role of physical exercise, microbiota and myokines. *Cells*, 2022, 11, s. 160.
- Zamboni, M. – Mazzali, G. – Fantin, F., et al.: Sarcopenic obesity: a new category of obesity in the elderly. *Nutr Metab Cardiovasc Dis*, 2008, 18, s. 388–395.
- Batsis, J. A. – Mackenzie, T. A. – Barre, L. K., et al.: Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III. *Eur J Clin Nutr*, 2014, 68, s. 1001–1007.
- Kim, Y. S. – Lee, Y. – Chung, Y. S., et al.: Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. *J Gerontol A Biol Sci Med Sci*, 2012, 67, s. 1107–1113.
- Hwang, B. – Lim, J. Y. – Lee, J., et al.: Prevalence rate and associated factors of sarcopenic obesity in Korean elderly population. *J Korean Med Sci*, 2012, 27, s. 748–755.
- Beaudart, C. – McCloskey, E. – Bruyère, O., et al.: Sarcopenia in daily practice: assessment and management. *BMC Geriatr*, 2016, 16, s. 170.
- Topinková, E.: Sarcopenia as a severe organ failure, its diagnosing and present therapeutic possibilities. *Vnitř Lek*, 2018, 64, s. 1038–1052.
- Bahat, G. – Erdoğan, T. – İlhan, B.: SARC-F and other screening tests for sarcopenia. *Curr Opin Clin Nutr Metab Care*, 2022, 25, s. 37–42.
- Nishikawa, H. – Asai, A. – Fukunishi, S., et al.: Screening tools for sarcopenia. *In Vivo*, 2021, 35, s. 3001–3009.
- Malmstrom, T. K. – Miller, D. K. – Simonsick, E. M., et al.: SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. *J Cachexia Sarcopenia Muscle*, 2016, 7, s. 28–36.
- Iida, S. – Kaneko, R. – Murata, K.: SARC-F for screening of sarcopenia among older adults: A meta-analysis of screening test accuracy. *J Am Med Dir Assoc*, 2018, 19, s. 685–689.
- Bischoff, H. A. – Stähelin, H. B. – Monsch, A. U., et al.: Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women. *Age Ageing*, 2003, 32, s. 315–320.
- Ortega-Bastidas, P. – Gómez, B. – Aqueveque, P., et al.: Instrumented Timed Up and Go Test (iTUG) – more than assessing time to predict falls: a systematic review. *Sensors*, 2023, 23, s. 3426.
- Mathias, S. – Nayak, U. S. – Isaacs, B.: Balance in elderly patients: the „get-up and go“ test. *Arch Phys Med Rehabil*, 1986, 67, s. 387–389.
- Podsiadlo, D. – Richardson, S.: The timed „Up & Go“: a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc*, 1991, 39, s. 142–148.
- Berková, M. – Topinková, E. – Mádlová, P., et al.: Krátká baterie pro testování fyzické zdatnosti seniorů – pilotní studie a validizační testu u starších osob v České republice. *Vnitř Lek*, 2013, 59, s. 256–263.
- Roberts, H. C. – Denison, H. J. – Martin, H. J., et al.: A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age Ageing*, 2011, 40, s. 423–429.
- Donini, L. M. – Bussetto, L. – Bischoff, S. C., et al.: Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO Consensus Statement. *Obes Facts*, 2022, 15, s. 321–335.
- Prachař, M., et al.: Sarkopenická obezita – aktuální přehled problematiky. *Vnitř Lek*, 2020, 66, s. 39–43.
- Dostupné z: https://cs.wikipedia.org/wiki/Occamova_břítva
- Wu, Y. – Wang, W. – Liu, T., et al.: Association of grip strength with risk of all-cause mortality, cardiovascular diseases, and cancer in community-dwelling populations: a meta-analysis of prospective cohort studies. *J Am Med Dir Assoc*, 2017, 18, s. 551.e17–551.e35.
- Huang, W. – Deng, S. – Liu, S., et al.: Association of metabolic syndrome and sarcopenia with all-cause and cardiovascular mortality: a prospective cohort study based on the NHANES. *Front Endocrinol*, 2024, 15, 1346669.
- Stenholm, S. – Mehta, N. K. – Elo, I. T., et al.: Obesity and muscle strength as long-term determinants of all-cause mortality—a 33-year follow-up of the Mini-Finland Health Examination Survey. *Int J Obes*, 2014, 38, s. 1126–1132.
- Benz, E. – Pinel, A. – Guillet, C., et al.: Sarcopenia and sarcopenic obesity and mortality among older people. *JAMA Netw Open*, 2024, 7, e243604.
- Doza, G. L. – van Heden, S. – Oliveira, F. F., et al.: Impact of interventions on sarcopenia from the perspective of older persons: a systematic literature review. *J Frailty Aging*, 2024, 13, s. 224–232.
- Billot, M. – Calvani, R. – Urtamo, A., et al.: Preserving mobility in older adults with physical frailty and sarcopenia: opportunities, challenges, and recommendations for physical activity interventions. *Clin Interv Aging*, 2020, 15, s. 1675–1690.
- Ghiotto, L. – Muollo, V. – Tatangelo, T., et al.: Exercise and physical performance in older adults with sarcopenic obesity: A systematic review. *Front Endocrinol*, 2022, 13, 913953.
- Kim, Y. C. – Ki, S. W. – Kim, H., et al.: Recent advances in nutraceuticals for the treatment of sarcopenic obesity. *Nutrients*, 2023, 15, s. 3854.
- Sanz-Cánovas, J. – López-Sampalo, A. – Cobos-Palacios, L., et al.: Management of type 2 diabetes mellitus in elderly patients with frailty and/or sarcopenia. *Int J Environ Res Public Health*, 2022, 19, s. 8677.
- Mikulecká, V. – Kvapil, M.: Mysleli jsme to dobře, a máme to dopadlo trochu jinak. Běžná příčina manifestace syndromu „frailty“ s dobrým koncem. *Kasuistiky v diabetologii*, 2022, 20, s. 20–23.